Untargeted metabolomic analysis of miltefosine action in Leishmania infantum reveals changes to the internal lipid metabolism

International Journal for Parasitology: Drugs and Drug Resistance

Volumn 4, Issue 1, 2014, Pages 20-27

  Vincent, Isabel M ^a   Weidt, Stefan ^b   Rivas, Luis ^c   Burgess, Karl ^b   Smith, Terry K ^d   Ouellette, Marc ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^d UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Leishmania; Metabolomics; Miltefosine; Mode of action

Indexed keywords

ALKANE; ANTIMONY; DNA FRAGMENT; MEMBRANE LIPID; MEMBRANE PHOSPHOLIPID; MILTEFOSINE; POLYAMINE; REACTIVE OXYGEN METABOLITE; SUGAR; THIOL;

ARTICLE; CELL DEATH; CELL MEMBRANE; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; DRUG RESISTANCE; DRUG TARGETING; DRUG UPTAKE; LEISHMANIA INFANTUM; LIPID METABOLISM; METABOLOMICS; NONHUMAN; OUTER MEMBRANE; PRIORITY JOURNAL; PROMASTIGOTE; WILD TYPE;

EID: 84890194600     PISSN: 22113207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpddr.2013.11.002     Document Type: Article

References (29)

1. Bligh E.G., Dyer W.J.A. Rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37(8):911-917.
2. Choudhurya K., Zandera D., Kube M., Reinhardt R., Clos J. Identification of a Leishmania infantum gene mediating resistance to miltefosine and SbIII. Int. J. Parasitol. 2008, 38(12):1411-1423.
3. Coelho A.C., Boisvert S., Mukherjee A., Leprohon P., Corbeil J., Ouellette M. Multiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencing. PLoS Negl. Trop. Dis. 2012, 6(2):e1512.
4. Creek D.J., Jankevics A., Burgess K.E., Breitling R., Barrett M.P. IDEOM: an Excel interface for analysis of LC-MS-based metabolomics data. Bioinformatics 2012, 28(7):1048-1049.
5. Croft S.L., Sundar S., Fairlamb A.H. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 2006, 19(1):111-126.
6. Dorlo T.P., Balasegaram M., Beijnen J.H., de Vries P.J. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J. Antimicrob. Chemother. 2012, 67:2576-2597.
7. Eisenberg T., Knauer H., Schauer A., Büttner S., Ruckenstuhl C., Carmona-Gutierrez D., Ring J., Schroeder S., Magnes C., Antonacci L., Fussi H., Deszcz L., Hartl R., Schraml E., Criollo A., Megalou E., Weiskopf D., Laun P., Heeren G., Breitenbach M., Grubeck-Loebenstein B., Herker E., Fahrenkrog B., Fröhlich K.U., Sinner F., Tavernarakis N., Minois N., Kroemer G., Madeo F. Induction of autophagy by spermidine promotes longevity. Nat. Cell Biol. 2009, 11(11):1305-1314.
8. Fairlamb A.H., Blackburn P., Ulrich P., Chait B.T., Cerami A. Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. Science 1985, 227(4693):1485-1487.
9. Getachew F., Gedamu L. Leishmania donovani mitochondrial iron superoxide dismutase A is released into the cytosol during miltefosine induced programmed cell death. Mol. Biochem. Parasitol. 2012, 183(1):42-51.
10. Hernández S.M., Sánchez M.S., de Tarlovsky M.N. Polyamines as a defense mechanism against lipoperoxidation in Trypanosoma cruzi. Acta Trop. 2006, 98(1):94-102.
11. Hornillos V., Carrillo E., Rivas L., Amat-Guerri F., Acuña A.U. Synthesis of BODIPY-labeled alkylphosphocholines with leishmanicidal activity, as fluorescent analogues of miltefosine. Bioorg. Med. Chem. Lett. 2008, 18(24):6336-6339.
12. Imbert L., Ramos R.G., Libong D., Abreu S., Loiseau P.M., Chaminade P. Identification of phospholipid species affected by miltefosine action in Leishmania donovani cultures using LC-ELSD, LC-ESI/MS, and multivariate data analysis. Anal. Bioanal. Chem. 2012, 402(3):1169-1182.
13. Lux H., Hart D.T., Parker P.J., Klenner T. Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkyl phospholipid analogues. Adv. Exp. Med. Biol. 1996, 416:201-211.
14. Moreira W., Leprohon P., Ouellette M. Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania. Cell Death Dis. 2011, 2:e201.
15. Pérez-Victoria F.J., Castanys S., Gamarro F. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob. Agents Chemother. 2003, 47(8):2397-2403.
16. Pérez-Victoria F.J., Gamarro F., Ouellette M., Castanys S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J. Biol. Chem. 2003, 278(50):49965-49971.
17. Pérez-Victoria J.M., Cortés-Selva F., Parodi-Talice A., Bavchvarov B.I., Pérez-Victoria F.J., Muñoz-Martínez F., Maitrejean M., Costi M.P., Barron D., Di Pietro A., Castanys S., Gamarro F. Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to miltefosine by inhibiting drug efflux. Antimicrob. Agents Chemother. 2006, 50(9):3102-3110.
18. PérezVictoria F.J., SánchezCañete M.P., Castanys S., Gamarro F. Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites. J. Biol. Chem. 2006, 281(33):23766-23775.
19. Proto W.R., Coombs G.H., Mottram J.C. Cell death in parasitic protozoa: regulated or incidental?. Nat. Rev. Microbiol. 2013, 11(1):58-66.
20. Rakotomanga M., Loiseau P.M., Saint-Pierre-Chazalet M. Hexadecylphosphocholine interaction with lipid monolayers. Biochim. Biophys. Acta 2004, 1661(2):212-218.
21. Rakotomanga M., Blanc S., Gaudin K., Chaminade P., Loiseau P.M. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 2007, 51(4):1425-1430.
22. Richmond G.S., Gibellini F., Young S.A., Major L., Denton H., Lilley A., Smith T.K. Lipidomic Analysis of bloodstream and procyclic form Trypanosoma brucei. Parasitology 2010, 137(9):1357-1392.
23. Ruiter G.A., Zerp S.F., Bartelink H., van Blitterswijk W.J., Verheij M. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 2003, 14(2):167-173.
24. Scheltema R.A., Jankevics A., Jansen R.C., Swertz M.A., Breitling R. PeakML/mzMatch: a file format, Java library, R library, and tool-chain for mass spectrometry data analysis. Anal. Chem. 2011, 83(7):2786-2793.
25. Seiferta K., Pérez-Victoria F.J., Stettler M., Sánchez-Cañete M.P., Castanys S., Gamarro F., Croft S.L. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int. J. Antimicrob. Agents 2007, 30(3):229-235.
26. Vincent I.M., Creek D.J., Burgess K., Woods D.J., Burchmore R.J., Barrett M.P. Untargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against Trypanosoma brucei. PLoS Negl. Trop. Dis. 2012, 6(5):e1618.
27. WHO, 2010. Working to overcome the global impact of neglected tropical diseases. First WHO report on neglected tropical diseases, WHO, Geneva.
28. Williams R.A.M., Smith T.K., Cull B., Mottram J.C., Coombs G.H. ATG5 is essential for autophagy and mitochondrial homeostasis in Leishmania. PLoS Pathog. 2012, 8(5):e1002695.
29. Zufferey R., Mamoun C.B. Choline Transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs. Mol. Biochem. Parasitol. 2002, 125:127-134.